Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.83
+$0.02 · +1.10%
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Latest quote
$1.83
+$0.02 · +1.10%
After-hours
$1.83
$0.00 · 0.00%
Oct 9, 4:01 PM ET
Regular session · ET · Market data may be delayed.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Day range
Current $1.83
52-week range
Current $1.83
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
56
Mixed
Risk
89
Extreme Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Day range
Current $1.83
52-week range
Current $1.83
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70M USD | — | — | — | — |
| Cost of goods sold | 325K USD | — | 437K USD | — | — |
| Gross profit | 69.68M USD | — | −437K USD | — | — |
| Research and development | 33.56M USD | 51.31M USD | 58.91M USD | 64.44M USD | 96.83M USD |
| Selling, general, and administrative | 16.57M USD | 27.47M USD | 27.11M USD | 28.39M USD | 30.04M USD |
| Operating expenses | 49.81M USD | 78.78M USD | 86.02M USD | 92.83M USD | 126.87M USD |
| Interest income | 4.06M USD | 2.18M USD | 1.92M USD | 2.03M USD | 3.46M USD |
| Depreciation and amortization | 325K USD | 343K USD | 437K USD | 508K USD | 205K USD |
| Operating income | 19.87M USD | −78.78M USD | −86.46M USD | −92.83M USD | −126.87M USD |
| Net income | 22.37M USD | −69.68M USD | −82.44M USD | −91.17M USD | −125.6M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.27M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.24M0.00%77.7B USD0.19%$278.94+0.49%
Fidelity Enhanced Small Cap ETFFESM1.14M0.02%6.41B USD0.28%$45.46+0.46%
Vanguard Extended Market ETFVXF1.07M0.00%95.4B USD0.05%$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV989.88K0.00%26.91B USD0.33%$37.95-0.39%
iShares Russell 2000 Value ETFIWN837.05K0.01%13.75B USD0.24%$210.87-0.04%
iShares Biotechnology ETFIBB689.38K0.01%10.41B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO571.83K0.00%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
